Daily Archive: November 15, 2011

Nov 15

Revolution in the management of aortic valve stenosis

There is unmet clinical need of standardized and safe modality of  treatment for severe degenerative calcific aortic stenosis especially in the high risk  population  who are older, frail and have multiple co morbidities, Writes Vijay Kumar and group from Fortis Escorts Heart Institute in the forthcoming CSI update being released in 63rd CSI early next …

Continue reading »

Nov 15

Cilostazol has anti depressant action

Cilostazol possesses antidepressant effect as evidenced through decrease in MADRS scoring as compared to baseline ratings and compared to control. Cilostazol could be a drug of choice in cardiovascular PCI patients associated with mild to moderate depression. Dr U Shah from Care Institute of Medical Sciences, Ahmedabad will be presenting the data in the forthcoming …

Continue reading »

Nov 15

PTMC improves LA function

The incidence of systemic embolism remains high in patients with mitral stenosis. The left atrial appendage (LAA) in patients with mitral stenosis is the preferential location of thrombi in patients with or without atrial fibrillation. v.Ganeswara reddy and group from Sri Venkateswra Institute of Medical Sciences, Tirupati, Andhra Pradesh has shown improvement in LAA function …

Continue reading »

Nov 15

AHA update:Vorapaxar Increases Bleeding in ACS

Giving a novel antiplatelet, vorapaxar, to acute coronary syndrome patients did not reduce mortality or serious cardiovascular events, but it did significantly increase the risk of major bleeding, including intracranial hemorrhage with a  35% increase in the relative risk of major bleeding events, and more than a three-fold increase in the risk of intracranial hemorrhage, …

Continue reading »

Nov 15

AHA update: Extended Apixaban Fails to Beat Enoxaparin for VTE

Medically ill patients at risk for venous thromboembolism did not obtain significant benefit from month-long treatment with apixaban  ( an anti coagulant) when compared with two weeks of treatment with the enoxaparin ( LMW Heparin), said Samuel Z. Goldhaber, MD, from Brigham & Women’s Hospital and Harvard Medical School in Boston.

Nov 15

AHA update: New-onset AF in sepsis

New onset atrial fibrillation in patients with severe sepsis is associated with a significant increase in in-hospital stroke and death compared with both sepsis patients who don’t develop AF and those with preexisting AF said Dr Allan Walkey of Boston University School of Medicine, MA. Their report is also published online November 13, 2011 in the Journal of …

Continue reading »

Nov 15

AHA update: ISAR-REACT 4: Bivalirudin preferable to abciximab/heparin in NSTEMI

The ISAR-REACT-4 trial has shown that bivalirudin is preferable to abciximab plus heparin in NSTEMI patients undergoing PCI.  In the trial also published online in the New England Journal of Medicine, the primary end point was not significantly different between the two groups, but bivalirudin was associated with less bleeding.

Nov 15

Facts and figures in cardiology

The Global Burden of Diseases study reported estimated mortality from CAD in India at 1.6 million in the year 2000. [Indian Heart J 2005; 57: 632-8]. Extrapolation of this estimate shows the current burden of CAD in India to be more than 32 million patients.